NCT02506816View on ClinicalTrials.gov

Preoperative Olaparib Endometrial Carcinoma Study (POLEN)

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

March 31, 2019

Conditions
Endometrial Carcinoma
Interventions
DRUG

Olaparib

Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).

Trial Locations (10)

14004

MedSIR investigative site, Córdoba

15006

MedSIR investigative site, A Coruña

15706

MedSIR investigative site, Santiago de Compostela

28034

MedSIR, Madrid

28040

MedSIR investigative site, Madrid

36312

MedSIR investigative site, Vigo

46009

MedSIR investigative site, Valencia

08035

MedSIR investigative site, Barcelona

08036

MedSIR investigative site, Barcelona

08400

MedSIR investigative site, Granollers

Sponsors

Collaborators (2)

AstraZeneca
Experior
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Experior

INDUSTRY

lead

MedSIR

OTHER